B&K Corp Ltd

02396

Company Profile

  • Business description

    B&K Corp Ltd is a China-based biopharmaceutical company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The company prominently focuses on the discovery, development and commercialization of therapies for wound healing, currently PDGF drugs. Its pipeline consisted of ten candidates, seven of which are PDGF candidates, including two Core Products, namely Pro-101-1 for the treatment of thermal burns and Pro-101-2 for the treatment of DFUs, which are rhPDGF-BB drugs. The company operates in a single reportable segment: the research and development of biopharmaceutical products.

  • Contact

    No. 19 Qinling Road, Xiexin Center
    Room 1507, Building 1
    Laoshan District
    Shandong Province
    Qingdao
    CHN

    http://www.huarenshengwu.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

Stocks News & Analysis

stocks

ASX miner weathers the storm with strong commodity prices

Lower volumes due cyclone activity but revenues hold steady.
stocks

Eli Lilly earnings: Mounjaro/Zepbound’s massive volume growth more than counters price pressure

We’ve raised our fair value estimate of Lilly stock.
stocks

OpenAI missed multiple revenue targets - here’s why it likely won’t IPO this year

Plus, whichever AI company IPOs first defines what “good” looks like.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,954.7021.20-0.24%
CAC 408,114.840.000.00%
DAX 4024,292.38337.821.41%
Dow JONES (US)49,499.27152.87-0.31%
FTSE 10010,363.9314.89-0.14%
HKSE25,776.53335.31-1.28%
NASDAQ25,114.44222.130.89%
Nikkei 22559,513.12228.200.38%
NZX 50 Index13,039.20135.891.05%
S&P 5007,230.1221.110.29%
S&P/ASX 2008,729.8021.20-0.24%
SSE Composite Index4,112.164.650.11%

Market Movers